DK2441454T3 - Anvendelse af isothiocyanatforbindelser til behandling af prostatitis - Google Patents
Anvendelse af isothiocyanatforbindelser til behandling af prostatitis Download PDFInfo
- Publication number
- DK2441454T3 DK2441454T3 DK11186579.6T DK11186579T DK2441454T3 DK 2441454 T3 DK2441454 T3 DK 2441454T3 DK 11186579 T DK11186579 T DK 11186579T DK 2441454 T3 DK2441454 T3 DK 2441454T3
- Authority
- DK
- Denmark
- Prior art keywords
- peitc
- isothiocyanates
- isothiocyanate
- oil
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Forbindelse af isothiocyanater, derivater eller metabolitter heraf til anvendelse ved behandling og/eller forebyggelse af prostatitis, hvor derivaterne og metabolitterne af isothiocyanater er valgt fra gruppen bestående af glutathionkonjugater af isothiocyanater, cysteinylglycinkonjugater af isothiocyanater, cysteinylkonjugater af isothiocyanater og N-acetylcysteinkonju-gater af isothiocyanater.
2. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor isothiocyanaterne er valgt fra gruppen bestående af benzylisothiocyanat (BITC), phenethylisothiocyanat (PEITC), allylisothiocyanat (AITC) og 4-sulfophenylisothiocyanat (SPITC), som har følgende formler henholdsvis (1), (2), (3) og (4) eller en kombination heraf:
3. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor derivaterne eller metabolitterne er valgt fra gruppen bestående af: N-acetylcysteinkonjugat af benzylisothiocyanat (BITC-NAC), N-acetylcysteinkonjugat af phenethylisothiocyanat (PEITC-NAC), N-acetylcysteinkonjugat af allylisothiocyanat (AITC-NAC) og N-acetylcysteinkonjugat af 4-sulfophenylisothiocyanat (SPITC-NAC), som har følgende formler henholdsvis (5), (6), (7) og (8) eller en kombination heraf:
4. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor isothiocyanaterne, derivater eller metabolitter heraf anvendes alene eller anvendes som en formulering med excipienser.
5. Forbindelse ifølge krav 1 til anvendelse ifølge krav 4, hvor formuleringen er valgt fra gruppen bestående af farmaceutisk produkt, kosttilskud, fødevare, kosmetisk produkt eller en kombination heraf.
6. Forbindelse ifølge krav 1 til anvendelse ifølge krav 4, hvor en sammensætning, som omfatter forbindelsen, indeholder følgende ingredienser: (a) aktive farmaceutiske ingredienser (API) af isothiocyanater, derivater heraf eller metabolitter heraf, hvor nævnte API er valgt fra gruppen bestående af phene-thylisothiocyanat (PEITC), benzylisothiocyanat (BITC), allyl-isothiocyanat (AITC), 4-sulfophenylisothiocyanat (SPITC), deres metabolitter af N-acetylcysteinkonju-gater eller en kombination heraf, og (b) en farmaceutisk acceptabel bærer for API, som indbefatter: (b1) overfladeaktive stoffer eller solubiliseringsmidler, hvor de overfladeaktive stoffer er valgt fra gruppen bestående af polyoxyethylenlaurylether, polyoxyethy-lenglycolmonostearat, E-vitamin-polyethylenglycolsuccinat, polyoxyethylenrici-nusolie, polyoxyethylen-hydrogeneret ricinusolie, poloxamer, polysorbater eller en kombination heraf, eller solubiliseringsmidlerne er valgt fra gruppen bestående af polyvinylpyrrolidon K17, K25, K30 eller K90, polyethylenglycol 400, 4000 eller 6000 eller en kombination heraf, (b2) olieingredienser, som er valgt fra gruppen bestående af fedtsyrer eller trigly-cerid, monoglycerid eller diglycerid, sojaolie, majsolie, jordnøddeolie, stearinsyre, palmitinsyre, palmeolie, solsikkeolie, olivenolie, kokosolie, sesamolie, bomuldsfrøolie, rapsolie, oliesyre, linolsyre, triglycerider med middellang kædelængde, glycerylmonooctadecanoat, glycerylmonoacetat, glyceryldiacetat, glyceryltriace-tat eller en kombination heraf, (b3) antioxidanter, som er vandopløselige antioxidanter eller fedtopløselige anti-oxidanter, som er valgt fra gruppen bestående af C-vitamin, C-vitamin-palmitat, propylgallat, tocopherol, tert-butyleret-p-hydroxyanisol, 2,6-di-tørf-butyl-p-methyl-phenol eller en kombination heraf, eller (b4) kombinationer af (b1), (b2) eller (b3).
7. Forbindelse ifølge krav 6 til anvendelse ifølge krav 6, hvor sammensætningen er et farmaceutisk produkt eller et kosttilskud.
8. Forbindelse ifølge krav 6 til anvendelse ifølge krav 6, hvor sammensætningen er valgt fra gruppen bestående af en tablet, en kapsel, en pille, pulver til injektionsvæske, injektionsvæske, lyofiliseret pulver, salve, suppositorie, creme, film, emulsion, spray, implantat eller en kombination heraf.
9. Forbindelse ifølge krav 6 til anvendelse ifølge krav 6, hvor sammensætningen foreligger i en form, som er beregnet til oral, intravenøs, muskulær, subkutan, intrakavitær, sublingual, anal eller topisk administration.
10. Forbindelse ifølge krav 6 til anvendelse ifølge krav 6, hvor sammensætningen anvendes alene eller i kombinerede terapier.
11. Forbindelse ifølge krav 6 til anvendelse ifølge krav 10, hvor de kombinerede terapier er valgt fra gruppen bestående af terapi med et eller flere af en vestlig medicinsk behandling eller traditionel kinesisk medicin, stråling, genterapi, biologiske produkter eller en kombination heraf.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510095737 CN1769268A (zh) | 2005-11-15 | 2005-11-15 | 一种天然及人工合成的异硫氰酸酯类化合物jc－5411在制备转录因子sp1的抑制剂中的应用 |
| CNA2006100381121A CN1840196A (zh) | 2006-01-27 | 2006-01-27 | 一种适用于难溶性药物的分散剂 |
| EP06817815A EP1961418B1 (en) | 2005-11-15 | 2006-11-14 | The use of isothiocyanates compounds in treating prostatic diseases and skin cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2441454T3 true DK2441454T3 (da) | 2015-12-21 |
Family
ID=38048290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06817815.1T DK1961418T3 (da) | 2005-11-15 | 2006-11-14 | Anvendelse af isothiocyanatforbindelser til behandling af prostatasygdomme og hudcancer |
| DK11186579.6T DK2441454T3 (da) | 2005-11-15 | 2006-11-14 | Anvendelse af isothiocyanatforbindelser til behandling af prostatitis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06817815.1T DK1961418T3 (da) | 2005-11-15 | 2006-11-14 | Anvendelse af isothiocyanatforbindelser til behandling af prostatasygdomme og hudcancer |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8039511B2 (da) |
| EP (2) | EP2441454B1 (da) |
| JP (1) | JP5308160B2 (da) |
| AT (1) | ATE552000T1 (da) |
| CA (1) | CA2630262C (da) |
| DK (2) | DK1961418T3 (da) |
| WO (1) | WO2007056941A1 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8665785B2 (en) * | 2009-09-11 | 2014-03-04 | Enversa Companies, Llc | Systems and methods for establishing a telecommunications bridge between a user device and a node |
| CN102160872A (zh) | 2010-02-23 | 2011-08-24 | 天津天士力制药股份有限公司 | 复方丹参滴丸胶囊 |
| US8414869B2 (en) * | 2010-11-30 | 2013-04-09 | N.V. Perricone Llc | Melanin promoting topical composition |
| US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
| US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
| US11279674B2 (en) | 2011-01-03 | 2022-03-22 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
| US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
| US11407713B2 (en) | 2011-01-03 | 2022-08-09 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
| US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
| US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
| US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
| US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
| WO2014018874A1 (en) | 2012-07-26 | 2014-01-30 | The William M. Yarbrough Foundation | Method for treating skin cancer |
| US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
| US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
| US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
| US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
| US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
| TWI495464B (zh) * | 2013-02-08 | 2015-08-11 | Univ Nat Taiwan | 苦味化合物於活化ｇｌｐ－１分泌之用途 |
| WO2015021929A1 (zh) | 2013-08-13 | 2015-02-19 | 无锡杰西医药科技有限公司 | 异硫氰酸酯类化合物与抗癌药物的联合应用 |
| US20160361380A1 (en) * | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| MX2020002894A (es) * | 2017-09-15 | 2020-10-07 | Tyme Inc | Formulaciones transdermicas. |
| DE102018121251A1 (de) * | 2018-08-30 | 2020-03-05 | Shenstone Consultants Ltd. | Isothiocyanate |
| CA3140042A1 (en) | 2019-05-14 | 2020-11-19 | Tyme, Inc. | Compositions and methods for treating cancer |
| CN114340594A (zh) * | 2019-07-10 | 2022-04-12 | 纳米技术有限责任公司(以生物科学博士名义) | 聚氨酯凝胶 |
| BR112022003636A2 (pt) | 2019-08-30 | 2022-05-24 | Grant Ind Inc | Elastômero de base biológica e biodegradável para cuidados pessoais e cosméticos |
| IT201900025840A1 (it) * | 2019-12-31 | 2021-07-01 | Univ Bologna Alma Mater Studiorum | Composti isotiocianati e isoselencianati |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2329238T3 (es) * | 2002-12-06 | 2009-11-24 | Dsm Ip Assets B.V. | Nuevo uso de licopeno para el tratamiento de enfermedades asociadas con la señalizacion de androgenos. |
| US20050070602A1 (en) * | 2003-09-30 | 2005-03-31 | Jen-Wei Chiao | Method of modulating immune response by administration of immuno-activation agent |
| CN100448845C (zh) * | 2005-06-30 | 2009-01-07 | 无锡杰西医药科技有限公司 | 一种天然及人工合成的异硫氰酸酯类化合物jc－5411在制备预防和治疗前列腺癌、肝癌、胃癌、肺癌、乳腺癌、宫颈癌、黑色素瘤和神经母细胞瘤的药物中的应用 |
| AU2007312941A1 (en) * | 2006-10-17 | 2008-04-24 | Summa Development Limited | Improved treatment for benign prostatic hyperplasia |
-
2006
- 2006-11-14 US US12/093,829 patent/US8039511B2/en active Active
- 2006-11-14 AT AT06817815T patent/ATE552000T1/de active
- 2006-11-14 DK DK06817815.1T patent/DK1961418T3/da active
- 2006-11-14 DK DK11186579.6T patent/DK2441454T3/da active
- 2006-11-14 CA CA2630262A patent/CA2630262C/en active Active
- 2006-11-14 EP EP11186579.6A patent/EP2441454B1/en active Active
- 2006-11-14 WO PCT/CN2006/003062 patent/WO2007056941A1/zh active Application Filing
- 2006-11-14 JP JP2008540431A patent/JP5308160B2/ja active Active
- 2006-11-14 EP EP06817815A patent/EP1961418B1/en active Active
-
2011
- 2011-09-13 US US13/231,406 patent/US8410170B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2441454B1 (en) | 2015-09-16 |
| CA2630262A1 (en) | 2007-05-24 |
| EP1961418B1 (en) | 2012-04-04 |
| US20120046358A1 (en) | 2012-02-23 |
| US8039511B2 (en) | 2011-10-18 |
| DK1961418T3 (da) | 2012-07-23 |
| EP1961418A1 (en) | 2008-08-27 |
| ATE552000T1 (de) | 2012-04-15 |
| CA2630262C (en) | 2011-11-08 |
| JP2009515910A (ja) | 2009-04-16 |
| WO2007056941A1 (fr) | 2007-05-24 |
| US8410170B2 (en) | 2013-04-02 |
| EP2441454A1 (en) | 2012-04-18 |
| US20090005438A1 (en) | 2009-01-01 |
| JP5308160B2 (ja) | 2013-10-09 |
| EP1961418A4 (en) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2441454T3 (da) | Anvendelse af isothiocyanatforbindelser til behandling af prostatitis | |
| Wong et al. | Pomegranate bioactive constituents target multiple oncogenic and oncosuppressive signaling for cancer prevention and intervention | |
| CN101091705B (zh) | 异硫氰酸酯类化合物在前列腺疾病及皮肤癌中的应用 | |
| JP5535999B2 (ja) | アンドロゲンによって仲介される疾患を治療するためのエクオールの使用 | |
| KR100741723B1 (ko) | 암 예방을 위한 하이드록시마타이레지놀 | |
| US20100297230A1 (en) | Compositions and methods for prostate and menstrual/menopausal related health | |
| Soumya et al. | GC-MS analysis of Cocus nucifera flower extract and its effects on heterogeneous symptoms of polycystic ovarian disease in female Wistar rats | |
| TW201805016A (zh) | 新穎之水飛薊(silybum marianum)瘦果萃取物以及其於皮膚科及皮膚化妝品的用途 | |
| Lee et al. | Lespedeza bicolor extract supplementation reduced hyperglycemia-induced skeletal muscle damage by regulation of AMPK/SIRT/PGC1α–related energy metabolism in type 2 diabetic mice | |
| EP3328498B1 (en) | Medical kit comprising herbal combinations for treating psoriasis | |
| JP2012520301A (ja) | エストロゲン化合物及びその使用方法 | |
| EP2628485B1 (en) | New use of chemical ingredients in cynomorium as phytoestrogen | |
| US10688146B2 (en) | Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems | |
| El-Newary et al. | Vitex Berries Attenuates Chemically-Induced Mammary Carcinomas in Rats through modulation of the cancer growth rate-limiting enzymes activities: aromatase and Na+/K+ ATPase. | |
| RU2803241C2 (ru) | КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ 7β-ГИДРОКСИХОЛЕСТЕРИН И ЛИПИДНЫЙ НОСИТЕЛЬ, И ЕЕ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ НЕОПЛАСТИЧЕСКИХ ПАТОЛОГИЙ | |
| KR102628223B1 (ko) | 노르갈란타민을 포함하는 간 손상의 예방 또는 치료용 조성물 | |
| Hu et al. | Effects of mixed formulation of tamoxifen and blue honeysuckle on the pharmacokinetics profiles of tamoxifen after single oral administration | |
| Toprak et al. | Effect of quercetin on perirenal adipose tissue adiponectin and resistin levels in rats with metabolic syndrome induced by high fructose-diet | |
| KR20120017498A (ko) | 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 함유하는 동맥경화 예방 및 치료용 조성물 | |
| Nicholson et al. | Consort Songs | |
| JP2010180153A (ja) | エストロジェン代替組成物 | |
| Ashok et al. | Formulation and Evaluation of Transdermal Patches of Tridax Procumbenes for Anti-Inflammatory Activity | |
| Ikezu et al. | Insilico Studies of activities of compounds from Ricinodendron heudelotii against inflammatory and oxidant enzymes Carbonic anhydrase |